Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04792931
Recruiting Not applicable

Adult Autoimmune Myopathies (MAIA)

NCT04792931 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Brest
Phase
Not applicable
Started
2022-05-20
Last updated
2026-06-25

Condition(s) studied

Idiopathic Inflammatory Myopathies

Investigational drug(s) / intervention(s)

description of adult autoimmune myopathies

description of adult autoimmune myopathies: description of adult autoimmune myopathies

Study summary

This study corresponds to a monocentric prospective cohort of adult patients presenting a suspicion of idiopathic inflammatory myopathy. It will allows the constitution of an organized collection of longitudinal clinical data as well as collection of biological samples, including blood sample, urine, stool and muscle specimen.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Clinical suspicion of Adult Inflammatory Myopathy * Social security affiliation Exclusion Criteria: * Pregnant and lactating women * Patients unable to consent * Patients refusing to participate in the research. * Patients under legal protection

Primary outcome measure(s)

  • Distribution of lymphocytes subpopulations (B, T and TH-17) — 6 months
    Distribution of lymphocytes subpopulations (B, T and TH-17) according to the final diagnosis defined by a panel of experts

Trial sites (1)

FacilityCityRegionStatus
CHU de BREST Brest France Recruiting

More University Hospital, Brest trials in France

Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure Recruiting
Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER ) Recruiting
Establishment of a Patient Library in Patients With Pruritus Sine Materia Recruiting
Recurrence of Thromboembolic Venous Disease of Atypical Location (RUSE) Active, not recruiting
Platelet Activity Monitoring for Patients Under Adp Medication Using Verify Now in Subdural Hematoma Starting soon

Other trials for the same condition

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies Starting soon
Phase 2 Study of Rapcabtagene Autoleucel in Myositis Active, not recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. Recruiting
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04792931 on ClinicalTrials.gov ↗ ← All trials in France